Peptides DB
Research-centric peptide and protocol reference hub
Study 12 of 15Triptorelin literatureScandinavian journal of urology and nephrology · RCT2011

Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.

Patients with previous cardiovascular disease face significant risks of cardiovascular events during treatment with high-dose PEP, while those without such history may have moderate risks.

Read at Scandinavian journal of urology and nephrologyAdd to compare

Where it sits

this study against the rest of the triptorelin corpus
1
Preclinical
10
Observational
0
Open-label
3
Randomised · this one
1
Reviews

Summary and findings

This study evaluated cardiovascular events in 915 hormone-naïve prostate cancer patients treated with either high-dose parenteral polyoestradiol phosphate (PEP) or combined androgen deprivation (CAD) including triptorelin. Significant increases in cardiovascular events were observed in patients with pretreatment cardiovascular morbidity. The study highlights the risks associated with PEP treatment in this population.

How much of this paper we could read: full text read (0.90). We had a clear abstract, so the summary below closely tracks the paper. What this means →
33% of patients with pretreatment cardiovascular diseases had a cardiovascular event during PEP treatment.2011

Abstract

The authors’ words, as Scandinavian journal of urology and nephrology supplied them

<h4>Objective</h4>This study aimed to evaluate prognostic risk factors for cardiovascular events during treatment of metastatic prostate cancer patients with high-dose parenteral polyoestradiol phosphate (PEP, Estradurin®) or combined androgen deprivation (CAD) with special emphasis on pretreatment cardiovascular disease.<h4>Material and methods</h4>Nine-hundred and fifteen patients with T0-4, Nx, M1, G1-3, hormone- naïve prostate cancer were randomized to treatment with PEP 240 mg i.m. twice a month for 2 months and thereafter monthly, or to flutamide (Eulexin®) 250 mg per os three times daily in combination with either triptorelin (Decapeptyl®) 3.75 mg i.m. per month or on an optional basis with bilateral orchidectomy. Pretreatment cardiovascular morbidity was recorded and cardiovascular events during treatment were assessed by an experienced cardiologist. A multivariate analysis was done using logistic regression.<h4>Results</h4>There was a significant increase in cardiovascular events during treatment with PEP in patients with previous ischaemic heart disease (p = 0.008), ischaemic cerebral disease (p = 0.002), intermittent claudication (p = 0.031) and especially when the whole group of patients with pretreatment cardiovascular diseases was analysed together (p < 0.001). In this group 33% of the patients had a cardiovascular event during PEP treatment. In the multivariate analysis PEP stood out as the most important risk factor for cardiac complications (p = 0.029). Even in the CAD group there was a significant increase in cardiovascular events in the group with all previous cardiovascular diseases taken together (p = 0.036).<h4>Conclusions</h4>Patients with previous cardiovascular disease are at considerable risk of cardiovascular events during treatment with high-dose PEP and even during CAD therapy. Patients without pretreatment cardiovascular morbidity have a moderate cardiovascular risk during PEP treatment and could be considered for this treatment if the advantages of this therapy, e.g. avoidance of osteopenia and hot flushes and the low price, are given priority.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Triptorelin corpus

CDevelopment and Preclinical Evaluation of Six-Transmembrane Epithelial Antigen of Prostate 2 Targeted PET Probes: A Case of Drug Repurposing Based on Molecular Docking.Journal of medicinal chemistry · 2016 · SUVmax 1.8 in 22Rv1 xenografts for 68Ga-Trip-5.AnimalBOvarian hyperstimulation-like syndrome after administration of triptorelin to a woman with endometriosis.Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2002 · Bilateral ovarian enlargement: right 74 x 62 mm, left 62 x 53 mm.HumanBGonadotropin-releasing hormone analog treatment for the prevention of treatment-related ovarian failure and infertility in women of reproductive age with Hodgkin lymphoma.Leukemia & lymphoma · 2008 · 50 patients (82%) recovered regular menses.HumanAThe two-shot protocol. A randomized controlled trial of a novel two-injection ovarian stimulation strategy.Human reproduction (Oxford, England) · 2023 · n=194 · Mean number of MII oocytes: 8.09 ± 5.87 vs 9.11 ± 6.86; MD -1.02 [95% CI: -2.83; 0.79]HumanAComparative effectiveness of luteal phase support strategies in natural cycle frozen-thawed embryo transfer: a systematic review and network meta-analysis.European journal of obstetrics, gynecology, and reproductive biology · 2026 · Not reported in abstract.reviewCProposed Method for Mass Spectrometric Measurement of the Gonadotropin-Releasing Hormone Agonist Deslorelin.Toxics · 2026 · Detectability optimized to <1 ppb.Animal